Taglich Updates ALR Technologies, Maintains 50 Cent Price Target

ALR Technologies (ALRT) Taglich Brothers

Analyst firm Taglich Brothers has updated their research report on ALR Technologies (OTCBB: ALRT). The New York-based firm has maintained their 50 cent, 12-month price target on ALRT and “Speculative Buy” rating based on five-year revenue potential for the company. Shares of ALRT closed trading on Wednesday at $0.0795; ahead 13.57% from Tuesday’s closing price.

The research update can be viewed here.

ALR Technologies Inc., based in Richmond, Virginia, has developed Heatlh-e-Connect (HeC), an FDA-cleared Internet-based system that links patients and clinicians. HeC records and transmits diagnostic data, e.g., self-monitored blood glucose data collected by patients, which can be uploaded to a personal computer and transmitted over the Internet to clinicians. The data is reviewed by clinicians who can communicate over HeC to patients or their caregivers. HeC is useful for managing patients with diabetes and other chronic diseases that lend themselves to self-monitoring, and for recording usage of self-monitoring test supplies. Data collected by HeC can also enable health insurers to monitor patient compliance by accurately tracking their consumption.

ALR Technologies (ALRT) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Touchdown!  NFL Refs Return to Field Thursday

Touchdown! NFL Refs Return to Field Thursday(0)

Not to knock the referees that filled-in during the lock-out of NFL officials as they did a pedestrian job, but the atrocious call on Monday Night Football between the Seahawks and the Packers was just about enough of the replacements.  Today, the National Football League said that a new eight-year deal with the NFL Referees

US Markets Drift Lower Ignoring Decent Economic Data

US Markets Drift Lower Ignoring Decent Economic Data(0)

U.S. stocks drifted lower Tuesday afternoon as worries about global economic growth overshadowed positive reports on the U.S. housing market and consumer confidence. The Dow Jones Industrial average was sharply lower, by 101.37 points, to finish at 13,457.50 The S&P 500 index subtracted 15.30 points, to 1,441.59, and the Nasdaq Composite Index got bruised 43.06

Stocks Still Fighting QE3 Hangover

Stocks Still Fighting QE3 Hangover(0)

U.S. stocks logged modest victories Thursday, after being stuck in the red for much of the day disappointing reports in Asia and Europe showed further signs of slowing global growth. The Dow Jones Industrial average was in the green 18.97 points to close Thursday at 13,596.70 The S&P 500 index fell short of breakeven by

Cardium Forms Excellagen Medical Advisory Board for Wound Care Product

Cardium Forms Excellagen Medical Advisory Board for Wound Care Product(0)

Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR),

Breast Cancer News:  Geron Drug Fails, Herceptin May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials

Breast Cancer News: Geron Drug Fails, Herceptin May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials(0)

Nobody said developing a new cancer drug was easy.  Geron Corp. (NASDAQ: GERN) shares took a nosedive last Monday, falling more than 50 percent as the drug maker disclosed that it is discontinuing a randomized Phase II clinical trial of its anti-cancer drug Imetelstat in metastatic HER2-negative breast cancer patients.  Menlo Park, California-based Geron said

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.